TempraMed Technologies Ltd. (CSE: VIVI; OTCQB: TMPTF; FSE: 9DY) announced that its VIVI Cap Smart medication-protection device now supports connectivity with Apple Health and Google Fit.
The October 5 update advances TempraMed’s effort to combine temperature protection with digital tracking for insulin pens, GLP-1 therapies and other injectable medications. VIVI Cap Smart is designed to record injection activity and temperature exposure while providing medication reminders and allowing information to be shared with caregivers, healthcare professionals and remote-patient-management systems.
Connecting with Apple Health and Google Fit could allow injection-related information to appear alongside other personal health data. TempraMed describes the product as pen-agnostic, meaning it is designed to work across multiple pen brands and therapy categories rather than being tied to one drug manufacturer.
“VIVI Cap Smart is about much more than protecting medication from heat and cold, it turns the injectable medication into a connected data point,” CEO Ron Nagar said.
The announcement does not disclose a commercial agreement with Apple or Google, subscription pricing, customer-adoption figures or revenue generated by the connectivity. It also does not provide clinical evidence showing that the integration improves adherence or health outcomes.
TempraMed said VIVI Cap Smart is intended to support a connected-device and subscription model, potentially adding software revenue to its existing hardware sales. That opportunity remains forward-looking and will depend on customer demand, technical performance, privacy requirements and continued access to third-party health platforms.
The company reported preliminary sales of approximately US$2.07 million for the eight months ended August 31, 2026, exceeding its approximately US$1.8 million in sales for all of 2025. Those interim sales figures had not been finalized when announced.
Financial capacity remains a consideration. TempraMed reported US$28,000 in cash, US$819,000 in current assets and US$3.25 million in current liabilities as of June 30, 2026. Revenue for the first six months was US$1.15 million, while the company recorded a US$4.14 million net loss and US$2.39 million in negative operating cash flow.
The filing identified material uncertainty that may cast significant doubt on TempraMed’s ability to continue as a going concern. After the quarter, the company raised approximately C$1.18 million through convertible debentures and units. The financing improved near-term liquidity but introduced interest obligations and potential shareholder dilution.
Upcoming Catalysts
- VIVI Cap Smart subscription pricing and rollout details
- User-adoption and recurring-revenue data
- Digital-health, pharmaceutical or remote-monitoring partnerships
- Conversion of distribution letters of intent into definitive agreements
- Final third-quarter financial and sales results
Sources
- TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit — Newsfile, October 5, 2026
- TempraMed Interim Financial Statements for the Period Ended June 30, 2026
- TempraMed Announces Closing of Private Placement — September 30, 2026
- FDA: Important Reminders About Medical-Device Registration and Listing
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, securities filings and regulatory sources. Securities discussed or referenced include TempraMed Technologies Ltd. (CSE: VIVI; OTCQB: TMPTF; FSE: 9DY). Biotech Stocks Daily has not received compensation from TempraMed, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include TempraMed’s October 5, 2026 connectivity announcement, its interim financial statements for the period ended June 30, 2026, its September 30, 2026 financing announcement and FDA guidance concerning device registration and listing. Product capabilities, preliminary sales figures, commercial expectations and potential benefits described by TempraMed have not been independently validated by Biotech Stocks Daily.
The announced connectivity does not establish a commercial partnership with, or endorsement by, Apple or Google. TempraMed did not disclose subscription pricing, customer-adoption data, revenue attributable to the integration or clinical evidence demonstrating improved adherence or patient outcomes. The company’s recurring-revenue and partnership expectations are forward-looking and may not be realized.
TempraMed describes its products as FDA-registered. The FDA states that registration and device listing do not denote approval, clearance or authorization. Readers should not interpret FDA registration as confirmation of a product’s safety, effectiveness or clinical benefit.
Financial figures from TempraMed’s interim filing are reported in U.S. dollars as of June 30, 2026. Financing figures are reported in Canadian dollars as of September 30, 2026. The company has reported continuing losses, negative operating cash flow and material uncertainty regarding its ability to continue as a going concern. Its recent financing included convertible debt, shares and warrants that may create interest costs and shareholder dilution.
These are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
